Neuronetics, Inc. (STIM)

Market Cap	250.78M
Revenue (ttm)	89.45M
Net Income (ttm)	-48.51M
Shares Out	65.82M
EPS (ttm)	-1.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	382,975
Open	3.820
Previous Close	3.820
Day's Range	3.750 - 3.870
52-Week Range	0.520 - 5.920
Beta	1.92
Analysts	Buy
Price Target	6.00 (+58.31%)
Earnings Date	Aug 11, 2025

About STIM

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company s...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jun 28, 2018
• Employees: 716
• Stock Exchange: NASDAQ
• Ticker Symbol: STIM
• Website: https://neurostar.com

Financial Performance

In 2024, Neuronetics's revenue was $74.89 million, an increase of 4.96% compared to the previous year's $71.35 million. Losses were -$43.71 million, 44.8% more than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for STIM stock is "Buy." The 12-month stock price forecast is $6.0, which is an increase of 58.31% from the latest price.

Price Target

$6.0

(58.31% upside)

Analyst Consensus: Buy